IDEAYA Biosciences is evolving from cash-burning clinical biotech to late-stage precision oncology launch story, with darovasertib’s H2 2026 NDA filing and a $1.30 billion cash war chest creating asymmetric upside if uveal melanoma execution stays on track.
Overview
IDEAYA Biosciences is a clinical-stage precision oncology company focused on synthetic lethality, biomarker-selected targeted therapies, and ADCs. The company has **no approved commercial products yet**, so current revenue comes from collaborations, licensing, and milestone payments, but it is approaching a major inflection as darovasertib advances toward a potential first U.S. launch. The lead asset targets PKC-driven uveal melanoma and has become the core value driver after ASCO 2026 data from OptimUM-02 showed median PFS of **6.9 months versus 3.1 months** for investigator choice therapy in first-line HLA-A2-negative metastatic uveal melanoma. That subgroup is strategically important because Kimmtrak is limited to HLA-A*02:01-positive patients, leaving 55% to 60% of the market underserved.
IDEAYA complements darovasertib with IDE397 in MTAP-deleted tumors and IDE849 in DLL3-expressing cancers, giving it a broader precision oncology platform beyond a single asset. Financially, the company ended Q1 2026 with $972.91 million in cash and then raised approximately **$323.6 million net** in June 2026, lifting pro forma cash to about **$1.30 billion** and extending runway into 2030. The near-term catalyst is the planned H2 2026 RTOR-enabled NDA filing for darovasertib. The investment case rests on clinical de-risking, protected market positioning, and unusually strong balance sheet support for a pre-commercial biotech.